Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2020-04-27 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
2019年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2019 年年度报告摘要" which translates to "2019 Annual Report Summary". It contains detailed financial data for the year 2019, including revenue, net profit, earnings per share, and changes in accounting policies. It also discusses business operations, industry position, shareholder information, and changes in consolidated subsidiaries. The length of the document (over 12,000 characters) and the presence of comprehensive financial and operational data indicate this is a substantive report, not merely an announcement or summary notice. The content aligns with the characteristics of an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year. Therefore, the correct classification is Annual Report (10-K). FY 2019
2020-04-27 Chinese
2019年度内部控制规则落实自查表
Audit Report / Information Classification · 95% confidence The document is titled '2019年度内部控制规则落实自查表' which translates to '2019 Annual Internal Control Rules Implementation Self-Inspection Form'. It contains detailed internal control checklists related to internal audit operations, information disclosure, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The content is focused on internal control compliance and audit-related self-assessment rather than full financial statements or management discussion. There is no indication of it being an annual report, audit report, or earnings release. It is a regulatory compliance document related to internal controls and audit processes, which fits best under Audit Report / Information (AR) as it relates to internal audit and control results but is not a full annual report. The document length is 4312 characters, which is substantive and not a mere announcement. Therefore, the classification is AR with high confidence. FY 2019
2020-04-27 Chinese
2019年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2019年度内部控制自我评价报告' which translates to '2019 Annual Internal Control Self-Evaluation Report'. It discusses the company's internal control system, evaluation of internal control effectiveness, risk assessment, internal audit, governance structure, and compliance with relevant regulations. The document is detailed and contains substantive content about internal control evaluation, including standards for identifying control deficiencies and conclusions about the absence of major deficiencies. It is not a general annual report or earnings release but a specialized report focused on internal control evaluation. This matches the description of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. The document is over 10,000 characters, indicating it is a full report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2019
2020-04-27 Chinese
2019年企业社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled '2019 年企业社会责任报告' (2019 Corporate Social Responsibility Report) and contains detailed sections on the company's social responsibility activities, governance, internal control, employee rights, quality management, customer rights, and social welfare. It references compliance with Shenzhen Stock Exchange social responsibility guidelines and covers the full year 2019. The content focuses on environmental, social, and governance (ESG) factors rather than financial results or audit opinions. The length is substantial (15,000 characters), indicating a full report rather than a brief announcement. Therefore, the document fits the category of Environmental & Social Information (SR).
2020-04-27 Chinese
独立董事关于第六届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 嘉事堂药业股份有限公司 regarding various matters discussed at the sixth board's seventh meeting. It includes independent opinions on the 2019 audit report, internal control self-evaluation, use of raised funds, related party transactions, profit distribution proposal, risk preference system, amendments to related party transaction management, reappointment of the audit firm, senior management remuneration system, and report on related party fund occupation. The document does not contain the full audit report or financial statements but rather the independent directors' review and opinions on these reports and proposals. It is a governance-related document reflecting board/management information and independent directors' opinions on corporate governance and financial matters. The document length is about 3060 characters, relatively short and focused on board opinions rather than full reports. Therefore, it fits best under Board/Management Information (MANG).
2020-04-27 Chinese
关于2019年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2019 annual profit distribution plan of the company 嘉事堂药业股份有限公司. It includes details about the profit distribution proposal, board and supervisory committee approvals, and independent director opinions. The document does not contain full financial statements or comprehensive financial performance data but rather focuses on the dividend distribution plan and related approvals. The document length is short (1627 characters) and it is an announcement of a profit distribution plan, which aligns with a Notice of Dividend Amount (DIV) filing type rather than a full Annual Report or Earnings Release. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2020-04-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.